How Is Systemic Lupus Erythematosus (SLE) Diagnosed?

Introduction

Systemic Lupus Erythematosus (SLE), commonly known as lupus, is a chronic autoimmune disorder characterized by the production of autoantibodies that attack the body’s own tissues and organs. It is a complex multisystem disease that can affect the skin, joints, kidneys, heart, lungs, blood vessels, nervous system, and hematological system. Due to its highly variable clinical presentation and the absence of a single definitive diagnostic test, the diagnosis of SLE often poses a challenge to clinicians. The diagnosis of SLE is established through a combination of clinical findings, laboratory investigations, immunological markers, and classification criteria. Laboratory tests play a crucial role in confirming autoimmune activity, assessing disease severity, evaluating organ involvement, and monitoring disease progression. This article discusses the key tests used in the diagnosis of SLE and their clinical significance.

Challenges in Diagnosing SLE

• SLE is often referred to as “the great imitator” because its symptoms can resemble those of many other diseases. Patients may present with fatigue, fever, joint pain, skin rashes, hair loss, kidney dysfunction, neurological symptoms, or blood abnormalities. Since these manifestations vary significantly among individuals, laboratory investigations become essential in establishing an accurate diagnosis.
• No single laboratory test can conclusively diagnose SLE. Instead, physicians rely on a combination of immunological and routine laboratory tests to support clinical suspicion. The tests that are important are as follows.

Antinuclear Antibody (ANA) Test

• The Antinuclear Antibody (ANA) test is the most important initial screening test for SLE.<
• ANA are autoantibodies directed against components of the cell nucleus. More than 95% of patients with SLE have a positive ANA test, making it highly sensitive for lupus.

Significance

1. Serves as the primary screening investigation.
2. A negative ANA makes active SLE unlikely.
3. Helps identify individuals requiring further autoimmune testing.

Interpretation

ANA results are usually reported as titers such as:

1. 1:40
2. 1:80
3. 1:160
4. 1:320
5. 1:640

Higher titers are generally more suggestive of autoimmune disease. However, ANA positivity is not specific for lupus and may also occur in:

1. Rheumatoid arthritis
2. Sjögren’s syndrome
3. Systemic sclerosis
4. Autoimmune thyroid disorders
5. Chronic infections
6. Healthy individuals

Therefore, a positive ANA alone does not confirm SLE and must be interpreted in conjunction with clinical findings and additional antibody tests

Anti-Double Stranded DNA (Anti-dsDNA) Antibody Test

• Anti-dsDNA antibodies are among the most specific autoantibodies associated with SLE.
• These antibodies target native double-stranded DNA present within the cell nucleus.

Clinical Importance

1. Highly specific for SLE.
2. Included in international classification criteria.
3. Useful in assessing disease activity.
4. Strongly associated with lupus nephritis.

Interpretation

1. Positive anti-dsDNA strongly supports the diagnosis of SLE.
2. Rising antibody levels often indicate increasing disease activity.
3. Elevated levels may precede lupus flares, especially renal flares.

Patients with active kidney involvement frequently exhibit high anti-dsDNA titers.

Anti-Smith (Anti-Sm) Antibody Test

Anti-Smith antibodies target proteins associated with small nuclear ribonucleoproteins (snRNPs).

Clinical Importance

1. Highly specific for SLE.
2. Rarely found in other autoimmune diseases.
3. Considered one of the most reliable confirmatory markers.

Interpretation

Although only a minority of lupus patients possess Anti-Sm antibodies, their presence strongly supports the diagnosis.

Key features include

1. High specificity
2. Moderate sensitivity
3. Valuable diagnostic confirmation

A positive Anti-Sm antibody is often considered almost diagnostic when clinical features are compatible with lupus.

Extractable Nuclear Antigen (ENA) Panel

The ENA panel evaluates several autoantibodies associated with connective tissue diseases.

Important antibodies include

Anti-Ro (SSA)

Associated with:

1. Cutaneous lupus
2. Photosensitivity
3. Neonatal lupus
4. Congenital heart block in newborns

Anti-La (SSB)

Commonly associated with:

1. Sjögren’s syndrome
2. Certain lupus cases

Anti-RNP

May be found in:

1. SLE
2. Mixed connective tissue disease

Clinical Significance

The ENA panel helps:

1. Differentiate lupus from other autoimmune disorders.
2. Identify specific disease manifestations.
3. Predict potential complications.

Complement Levels (C3 and C4)

• The complement system consists of proteins involved in immune defense and inflammation.
• In SLE, immune complexes activate the complement pathway, resulting in complement consumption.

Important Tests

1. Complement C3
2. Complement C4
3. CH50 (Total complement activity)

Clinical Significance

Low complement levels suggest:

1. Active disease
2. Immune complex formation
3. Lupus nephritis

Interpretation

1. Reduced C3 and C4 often indicate disease activity.
2. Persistent complement depletion may reflect ongoing inflammation.
3. Monitoring complement levels helps assess treatment response.

Complete Blood Count (CBC)

A Complete Blood Count provides valuable information regarding hematological abnormalities frequently seen in lupus.

Common Findings

Anemia

May occur due to:

1. Chronic inflammation
2. Iron deficiency
3. Autoimmune hemolysis
4. Kidney disease

1. Leukopenia

Low white blood cell count is commonly observed in SLE.

2. Lymphopenia

Reduction in lymphocyte count is a characteristic laboratory abnormality.

3. Thrombocytopenia

Low platelet count may increase bleeding risk and indicate immune-mediated destruction.

Clinical Importance

CBC abnormalities contribute to classification criteria and help evaluate disease severity.

Erythrocyte Sedimentation Rate (ESR)

ESR measures the rate at which red blood cells settle in a test tube over one hour.

Significance

• Reflects systemic inflammation.
• Frequently elevated during active lupus.

Clinical Utility

An elevated ESR may suggest:

1. Active disease
2. Infection
3. Inflammatory processes

Although nonspecific, ESR is often used for disease monitoring.

C-Reactive Protein (CRP)

CRP is another marker of inflammation produced by the liver

Importance in SLE

Unlike many inflammatory diseases, CRP may remain normal during lupus flares.

Clinical Significance

Marked CRP elevation may indicate:

1. Concurrent infection
2. Serositis
3. Severe inflammatory activity

Comparing ESR and CRP often helps clinicians distinguish lupus activity from infection.

Urinalysis

• Kidney involvement occurs in a significant proportion of SLE patients and can lead to serious complications.
• Routine urinalysis is therefore an essential investigation.

Parameters Evaluated

1. Proteinuria
2. Hematuria
3. Cellular casts
4. White blood cells

Clinical Importance

Abnormal urinalysis findings may indicate:

1. Lupus nephritis
2. Active renal inflammation
3. Kidney damage

Regular urine examination allows early detection of renal involvement.

Urine Protein Assessment

Protein leakage in urine is one of the hallmark features of lupus nephritis.

Common Tests

• Urine Protein-to-Creatinine Ratio (UPCR)
• Provides a convenient estimate of daily protein excretion.

24-Hour Urine Protein

Measures total protein loss over 24 hours.

Clinical Significance

Higher protein excretion generally correlates with greater kidney involvement and disease severity.

Kidney Function Tests

Renal assessment is vital because lupus nephritis significantly affects prognosis.

Important Parameters

1. Serum creatinine
2. Blood urea nitrogen (BUN)
3. Estimated glomerular filtration rate (eGFR)

Clinical Importance

Abnormal kidney function tests may indicate:

1. Active nephritis
2. Chronic kidney damage
3. Reduced renal filtration capacity

These tests help determine the extent of kidney involvement and guide treatment decisions.

Antiphospholipid Antibody Testing

Many lupus patients develop antiphospholipid antibodies, which increase the risk of blood clot formation.

Key Tests

1. Lupus Anticoagulant
2. Assesses clotting abnormalities.
3. Anticardiolipin Antibody
4. Detects antibodies against phospholipid-binding proteins.
5. Anti-β2 Glycoprotein I Antibody
6. Evaluates thrombosis risk.

Clinical Importance

Positive results may indicate:

1. Antiphospholipid syndrome (APS)
2. Increased risk of venous thrombosis
3. Recurrent miscarriages
4. Stroke risk

Identification of these antibodies is crucial for preventing complications.

Direct Coombs Test

The Direct Coombs Test detects antibodies attached to red blood cells.

Significance

Positive results suggest:

1. Autoimmune hemolytic anemia
2. Immune-mediated red cell destruction

Clinical Relevance

Hemolytic anemia is a recognized manifestation of SLE and contributes to disease classification.

Kidney Biopsy

Although not a routine screening test, kidney biopsy is often required when lupus nephritis is suspected.

Indications

• Significant proteinuria
• Declining kidney function
• Persistent urinary abnormalities

Importance

Kidney biopsy

1. Confirms lupus nephritis.
2. Determines histological class.
3. Guides treatment selection.
4. Helps predict prognosis.

The biopsy findings are classified according to internationally accepted lupus nephritis classes.

Skin Biopsy

In patients with prominent skin lesions, a skin biopsy may provide supportive evidence.

Findings

Histological examination may reveal

1. Interface dermatitis
2. Immune complex deposition
3. Basement membrane abnormalities

Direct immunofluorescence may demonstrate the characteristic “lupus band.

Classification Criteria and Laboratory Testing

Modern diagnostic approaches utilize classification systems such as the European Alliance of Associations for Rheumatology (EULAR) and the American College of Rheumatology (ACR) criteria.

Key laboratory parameters incorporated into these criteria include:

1. Positive ANA
2. Anti-dsDNA antibodies
3. Anti-Sm antibodies
4. Low complement levels
5. Antiphospholipid antibodies
6. Hematological abnormalities
7. Proteinuria

These laboratory findings are combined with clinical manifestations to establish the diagnosis.

Conclusion

The Diagnosis of Systemic Lupus Erythematosus requires a comprehensive evaluation that integrates clinical symptoms with a variety of laboratory investigations. Among all tests, the ANA test serves as the primary screening tool, while anti-dsDNA and anti-Smith antibodies provide strong diagnostic support. Complement levels, CBC abnormalities, urinalysis, kidney function tests, and antiphospholipid antibody testing offer valuable information regarding disease activity and organ involvement. Because SLE is a multisystem autoimmune disease with diverse presentations, no single test is sufficient for diagnosis. Instead, clinicians rely on a combination of serological markers, inflammatory indicators, hematological findings, and organ-specific assessments to confirm the disease. Early and accurate diagnosis through these investigations allows timely treatment, reduces organ damage, and improves long-term patient outcomes.